BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 34972965)

  • 1. Landscape of Immunotherapy in Genitourinary Malignancies.
    Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
    Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Landscape of Immunotherapy in Genitourinary Malignancies.
    Alhalabi O; Rafei H; Bilen MA; Shah AY
    Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
    Lu K; Chiu KY; Cheng CL
    Cancer Treat Res; 2022; 183():201-223. PubMed ID: 35551661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of immunotherapy in clinical management of genitourinary cancers - a review.
    Mar N; Uchio E; Kalebasty AR
    Cancer Treat Res Commun; 2022; 31():100564. PubMed ID: 35472699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promise of immunotherapy in genitourinary malignancies.
    Zhang T; Armstrong AJ; George DJ; Huang J
    Precis Clin Med; 2018 Dec; 1(3):97-101. PubMed ID: 30687563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
    Surolia I; Gulley J; Madan RA
    Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors.
    Bahlinger V; Hartmann A; Eckstein M
    Adv Anat Pathol; 2023 May; 30(3):203-210. PubMed ID: 36730368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Kato M; Uchida J
    Int J Urol; 2023 Dec; 30(12):1068-1077. PubMed ID: 37602512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-Oncology Advances in Genitourinary Cancers.
    Zang PD; Angeles A; Dorff TB; Pal SK; Gupta S
    Am Soc Clin Oncol Educ Book; 2024 Jan; 44(2):e430428. PubMed ID: 38206274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
    Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
    Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in genitourinary malignancies.
    Wattenberg MM; Fong L; Madan RA; Gulley JL
    Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current State of Cell Therapies for Genitourinary Malignancies.
    Alkhouli MA; Bazargan S; Pilon-Thomas S; Poch M; Chahoud J
    Cancer J; 2022 Jul-Aug 01; 28(4):294-300. PubMed ID: 35880939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal Selection of Patients with Genitourinary Cancers for Anti-PD1/PD-L1 Treatment with a Focus on Urothelial and Renal Cell Carcinoma.
    Zeuschner P; Junker K
    Eur Urol Focus; 2022 Jul; 8(4):907-909. PubMed ID: 35918269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
    Meza L; Malhotra J; Favorito C; Pal SK
    Future Oncol; 2022 Jan; 18(1):21-33. PubMed ID: 34766841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunotherapy revolution in genitourinary malignancies.
    U Gandhy S; Madan RA; Aragon-Ching JB
    Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
    Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
    Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Teo MY; Rosenberg JE
    Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel immunotherapy combinations for genitourinary cancers.
    Al Harthy M; Redman J; Madan RA
    Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.